Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
2,246 total articles
Coeur Mining (CDE) is trading at $24.37 with a market cap around $15.6B despite a recently reported 4.4M oz of proven and probable gold reserves valued at roughly $22.1B at current gold. The balance sheet is clean, free cash flow is robust ($665.7M last reported), and technicals show short-term momentum. This trade idea buys that gap between reserv…
Hubbell combines stable electrical-products cash flow with a timely push into high-voltage grid infrastructure via the DMC Power deal. Fundamentals and technicals favor a measured long entry; valuation is rich but supported by high returns and free cash flow. Trade plan included with clear entry, stop and target for a long-term (180 trading days) s…
Micron sits at the intersection of a structural AI demand boom and acute memory supply tightness. With HBM capacity sold out, gross margins expanding, a market cap near $485B and improving fundamentals, MU looks like a buyable long for investors who want exposure to AI infrastructure without buying GPUs. This trade idea lays out an entry at $431.22…
Materialise (MTLS) looks set for a rebound supported by its recurring-software revenue and improving demand in medical additive manufacturing. At a market cap of ~$305M and current price near $5.16, the risk/reward for a mid-term swing is attractive: enter $5.20, stop $4.80, target $6.40 (primary) and $7.20 (secondary). Key catalysts include trade …
Apollo Global (APO) is down with the recent private-credit scare, but fundamentals — $938B AUM, record origination >$300B, $225B+ inflows and a $0.51 quarterly dividend — argue for a tactical long. Technicals are oversold (RSI ~29), short interest elevated, and the market is treating a diversified credit/PE manager like a growth software multiple. …
Canada Goose (GOOS) is a tactical buy after better-than-feared holiday demand, fresh institutional buying, and signs of technical stabilization. The name trades at $12.15 with a market cap of roughly $1.19B, a P/E of 83.9 and notable short interest. Our plan targets a move back toward recent highs near $15.50 over a mid-term (45 trading days) horiz…
Conagra trades at a low multiple (P/S ~0.8, EV/EBITDA ~10.3) with $876M of free cash flow and a 7.4% dividend yield. Guidance is muted and profitability is pressured, but valuation and cash generation provide a floor. This trade targets a recovery toward $24 over a 180-trading-day window with a stop at $16 to limit downside if fundamentals deterior…
Microsoft has fallen roughly 30% from its 52-week high to about $386.90 today, pushing valuation down to the mid-20s on P/E while fundamentals - $77.4B free cash flow, 30%+ ROE, and dominant cloud positions - remain intact. This trade idea recommends a tactical long entry at $386.90 with a stop at $360.00 and a primary target of $430.00 (mid-term) …
Upwork's recent guidance reset and slower GSV outlook have prompted a downgrade in conviction, but the company is cash-generative, profitable on GAAP, and gaining traction with AI-enabled product improvements. For nimble traders, a mid-term long with a tight stop captures upside from buybacks and AI adoption while limiting exposure to demand risks.
CTS Corporation (CTS) designs and manufactures sensors, actuators and connectivity components for aerospace, industrial, medical and transportation customers. With a $1.55B market cap, positive free cash flow of $80.2M, low leverage and a 52-week range that still leaves upside to $65, we maintain an Overweight stance and propose an actionable long …
Daktronics' buy of X Display assets gave it proprietary MicroLED mass-transfer and fabrication IP at a time when narrow-pixel-pitch (NPP) demand is growing. With a $360M backlog, improving order flow, and a clear margin target, the stock looks set to re-rate if MicroLED ramps and narrow-pitch products push gross margins higher. This trade targets a…
Synopsys (SNPS) is a leader in electronic design automation and semiconductor IP with durable customer lock-in. Recent sector multiple compression and integration concerns around the Ansys deal knocked the stock down ~33% from its 52-week high. That dislocation creates a long trade with defined risk and attractive upside if execution stabilizes and…
Anthropic's new tools spooked the market this week, but IBM's mix of software, consulting, and infrastructure - anchored by Red Hat and recurring cash flows - is resilient to narrow automation threats. IBM screens as a buy at $235.43 with a 180-trading-day horizon based on free cash flow strength, an attractive dividend, and an oversold technical s…
ONEOK (OKE) offers a compelling income-and-value trade after Q4: mid-single-digit growth in cash flow, a 4.7% yield, and valuation metrics that imply upside if economic activity and NGL throughput normalize. This trade idea lays out entry, stop, target, catalysts and risks for a long position over the next 180 trading days.
Novo Nordisk's stock has been punished after the REDEFINE 4 readout for CagriSema, but the sell-off has created a tradeable opportunity. The company still controls leading diabetes and obesity franchises, trades at ~11x earnings with a $177B market cap, and is handing investors a 3.1% dividend yield. This trade targets a recovery as the market re-p…
Hewlett Packard Enterprise is digesting a large networking acquisition, leaning into GreenLake and AI infrastructure partnerships. At current levels the stock offers a risk/reward skewed to the upside for a long trade, supported by 3% yield, $627M free cash flow and a sub-$27 market cap. Execution and margin recovery are the key watchpoints.
Nano Labs has shifted strategy in 2025 from fabless chip growth to building crypto reserves (primarily BNB) while slashing operating costs. The move compresses traditional revenue growth prospects but creates an asymmetric trade: a low current market cap ($73.8M) and insider buying versus weak recent revenue and a pivot-dependent thesis. I lay out …
Netskope plunged after a guidance-driven sell-off, but fundamentals remain intact: 33% reported sales growth, 118% net retention, new AI-enabled product launches and enterprise tailwinds for SASE. At a $3.64B market cap and deeply oversold technicals (RSI ~22), this dip is an asymmetric trade. Aggressive buyers can establish a position at $9.29 wit…
Hims & Hers (HIMS) has been hammered by an FDA crackdown and a patent suit tied to its copycat GLP-1 pill, sending the stock to 52-week lows. The sell-off appears disproportionate relative to a still-profitable telehealth core: $3.54B market cap, positive free cash flow, and a leverageable acquisition pipeline. This trade idea lays out a mid-term (…
Nuveen New York Quality Municipal Income Fund (NAN) is trading near the top of its 52‑week range with strong short activity and limited near‑term dividend support. For traders willing to accept elevated risk, a mid‑term short targeting mean reversion to the low end of the range offers an asymmetric payoff with defined entry, stop and target.
Acadia Healthcare is a beaten-down behavioral-health operator trading at value multiples while short interest sits above 30% of the float. With bullish momentum, activist ownership, and litigation clarity possible, this is a tactical long with a clearly defined stop and mid-term horizon to capture a potential short squeeze and re-rating.
Archer Aviation (ACHR) is a pre-revenue eVTOL maker with a $5.1B market cap that just secured a concrete operating plan tied to LA28 through its Hawthorne Airport deal. That operational foothold, combined with a large institutional stake and improving technicals, creates a tradeable long with a defined entry, stop and target for a long-term (180 tr…
Uber's stock is trading well below its 52-week high despite healthy free cash flow, improving profitability and concrete growth catalysts (autonomy, European delivery expansion). Market uncertainty has compressed the multiple; we present a staged long trade with defined entry, stop and target that balances upside with near-term volatility risks.
Travere's FILSPARI (sparsentan) is now the center of the company's revenue story and a near-term regulatory binary that could re-rate the stock. At $30.75 the fundamentals and technicals suggest a tactical long: entry at $30.50, stop at $25.00, and a target at $42.00 tied to prior highs and potential approval/launch upside.
<p>American Shared Hospital Services (AMS) looks mispriced. Recent headlines around automation and AI replacing clinical services have pushed sentiment lower for capital-intensive, people-driven treatment providers. That worry is misplaced for a company that leases Gamma Knife and other radiosurgery equipment, reported 17% revenue growth in Q1 2025…
